 Connection
Michael DiStefano to United States
This is a "connection" page, showing publications Michael DiStefano has written about United States.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.548 |
|
|
|
-
DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.
Score: 0.074
-
DiStefano MJ, Zemplenyi A, McQueen RB. Assessing clinical benefit in the Medicare Drug Price Negotiation Program: A 2-step approach for improving transparency, consistency, and meaningful patient engagement. J Manag Care Spec Pharm. 2024 Mar 01; 30(3):252-258.
Score: 0.074
-
DiStefano MJ, Levy JF, Odouard IC, Anderson GF. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations. Value Health. 2023 11; 26(11):1618-1624.
Score: 0.072
-
DiStefano MJ, Kang SY, Parasrampuria S, Anderson GF. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance. JAMA Health Forum. 2023 05 05; 4(5):e231090.
Score: 0.070
-
DiStefano MJ, Markell JM, Doherty CC, Alexander GC, Anderson GF. Association Between Drug Characteristics and Manufacturer Spending on Direct-to-Consumer Advertising. JAMA. 2023 02 07; 329(5):386-392.
Score: 0.069
-
DiStefano MJ, Alexander GC, Polsky D, Anderson GF. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey. J Am Geriatr Soc. 2022 06; 70(6):1685-1694.
Score: 0.065
-
DiStefano MJ, Kang SY, Yehia F, Morales C, Anderson GF. Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs. Value Health. 2021 03; 24(3):397-403.
Score: 0.060
-
Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola ND, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. Pharmacoeconomics. 2024 Mar; 42(3):319-328.
Score: 0.018
-
Anderson KE, DiStefano MJ, Liu A, Mattingly TJ, Socal MP, Anderson GF. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs. Value Health. 2023 09; 26(9):1381-1388.
Score: 0.018
-
Kang SY, Bai G, DiStefano MJ, Socal MP, Yehia F, Anderson GF. Comparative Approaches to Drug Pricing. Annu Rev Public Health. 2020 04 02; 41:499-512.
Score: 0.014
-
Kang SY, DiStefano MJ, Socal MP, Anderson GF. Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries. Health Aff (Millwood). 2019 05; 38(5):804-811.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|